{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:01:18Z","timestamp":1791266478688,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AG059417-01A1"],"award-info":[{"award-number":["1R01AG059417-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Trial of Parkinson\u2019s And Zoledronic acid (TOPAZ, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03924414\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03924414<\/jats:ext-link>) is a unique collaboration between experts in movement disorders and osteoporosis to test the efficacy of zoledronic acid, an FDA-approved parenteral treatment for osteoporosis, for fracture prevention in people with neurodegenerative parkinsonism. Aiming to enroll 3,500 participants age 65 years or older, TOPAZ is one of the largest randomized, placebo-controlled clinical trials ever attempted in parkinsonism. The feasibility of TOPAZ is enhanced by its design as a U.S.- wide home-based trial without geographical limits. Participants receive information from multiple sources, including specialty practices, support groups and websites. Conducting TOPAZ in participants\u2019 homes takes advantage of online consent technology, the capacity to confirm diagnosis using telemedicine and the availability of research nursing to provide screening and parenteral therapy in homes. Home-based clinical research may provide an efficient, convenient, less expensive method that opens participation in clinical trials to almost anyone with parkinsonism.<\/jats:p>","DOI":"10.1038\/s41531-021-00162-1","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T11:07:32Z","timestamp":1614596852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-5082","authenticated-orcid":false,"given":"Caroline M.","family":"Tanner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-8562","authenticated-orcid":false,"given":"Ethan G.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ray","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B.","family":"Galifianakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-3445","authenticated-orcid":false,"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nijee","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus R.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2921-8348","authenticated-orcid":false,"given":"David G.","family":"Standaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Greenspan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4884-9893","authenticated-orcid":false,"given":"James C.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Lyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"162_CR1","doi-asserted-by":"publisher","first-page":"115173","DOI":"10.1016\/j.bone.2019.115173","volume":"132","author":"M Schini","year":"2020","unstructured":"Schini, M. et al. The risk of hip and non-vertebral fractures in patients with Parkinson\u2019s disease and parkinsonism: a systematic review and meta-analysis. Bone 132, 115173 (2020).","journal-title":"Bone"},{"key":"162_CR2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.L.01317","volume":"96","author":"M Harris-Hayes","year":"2014","unstructured":"Harris-Hayes, M. et al. Relative mortality in U.S. Medicare beneficiaries with Parkinson disease and hip and pelvic fractures. J. Bone Jt. Surg. Am. 96, e27 (2014).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"162_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.parkreldis.2012.01.004","volume":"18","author":"AJ Yarnall","year":"2012","unstructured":"Yarnall, A. J., Duncan, G. W., Khoo, T. K. & Burn, D. J. Falling short: underestimation of fracture risk in atypical parkinsonian syndromes. Parkinsonism Relat. Disord. 18, 692\u2013693 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"162_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/jnnp.2005.074070","volume":"77","author":"DR Williams","year":"2006","unstructured":"Williams, D. R., Watt, H. C. & Lees, A. J. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J. Neurol. Neurosurg. Psychiatry 77, 468\u2013473 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"162_CR5","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1111\/jgs.14474","volume":"64","author":"DC Mackey","year":"2016","unstructured":"Mackey, D. C. et al. Life-space mobility and mortality in older women: prospective results from the study of osteoporotic fractures. J. Am. Geriatr. Soc. 64, 2226\u20132234 (2016).","journal-title":"J. Am. Geriatr. Soc."},{"key":"162_CR6","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/jbmr.3030","volume":"31","author":"SR Cummings","year":"2016","unstructured":"Cummings, S. R. & Eastell, R. Risk and prevention of fracture in patients with major medical illnesses: a mini-review. J. Bone Min. Res. 31, 2069\u20132072 (2016).","journal-title":"J. Bone Min. Res."},{"key":"162_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ageing\/afu122","volume":"44","author":"V Lyell","year":"2015","unstructured":"Lyell, V., Henderson, E., Devine, M. & Gregson, C. Assessment and management of fracture risk in patients with Parkinson\u2019s disease. Age Ageing 44, 34\u201341 (2015).","journal-title":"Age Ageing"},{"key":"162_CR8","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00198-012-2221-5","volume":"24","author":"C Hansen","year":"2013","unstructured":"Hansen, C., Pedersen, B. D., Konradsen, H. & Abrahamsen, B. Anti-osteoporotic therapy in Denmark-predictors and demographics of poor refill compliance and poor persistence. Osteoporos. Int. 24, 2079\u20132097 (2013).","journal-title":"Osteoporos. Int."},{"key":"162_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809\u20131822 (2007).","journal-title":"N. Engl. J. Med."},{"key":"162_CR10","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles, K. W. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357, 1799\u20131809 (2007).","journal-title":"N. Engl. J. Med."},{"key":"162_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1210\/jc.2012-2868","volume":"98","author":"IR Reid","year":"2013","unstructured":"Reid, I. R. et al. Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J. Clin. Endocrinol. Metab. 98, 557\u2013563 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"162_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1210\/jc.2008-2241","volume":"94","author":"A Grey","year":"2009","unstructured":"Grey, A. et al. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J. Clin. Endocrinol. Metab. 94, 538\u2013544 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"162_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","volume":"175","author":"SL Greenspan","year":"2015","unstructured":"Greenspan, S. L., Perera, S., Ferchak, M. A., Nace, D. A. & Resnick, N. M. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern. Med. 175, 913\u2013921 (2015).","journal-title":"JAMA Intern. Med."},{"key":"162_CR14","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid, I. R. et al. Fracture prevention with zoledronate in older women with osteopenia. N. Engl. J. Med. 379, 2407\u20132416, https:\/\/doi.org\/10.1056\/NEJMoa1808082 (2018).","journal-title":"N. Engl. J. Med."},{"key":"162_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/mds.870080326","volume":"8","author":"JP Hubble","year":"1993","unstructured":"Hubble, J. P., Pahwa, R., Michalek, D. K., Thomas, C. & Koller, W. C. Interactive video conferencing: a means of providing interim care to Parkinson\u2019s disease patients. Mov. Disord. 8, 380\u2013382 (1993).","journal-title":"Mov. Disord."},{"key":"162_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/mds.23145","volume":"25","author":"ER Dorsey","year":"2010","unstructured":"Dorsey, E. R. et al. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson\u2019s disease. Mov. Disord. 25, 1652\u20131659 (2010).","journal-title":"Mov. Disord."},{"key":"162_CR17","doi-asserted-by":"publisher","unstructured":"Stoessl, A. J., Bhatia, K. P. & Merello, M. Editorial: movement disorders in the world of Covid-19. Mov. Disord. https:\/\/doi.org\/10.1002\/mds.28069 (2020).","DOI":"10.1002\/mds.28069"},{"key":"162_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cct.2014.04.009","volume":"38","author":"M Orri","year":"2014","unstructured":"Orri, M., Lipset, C. H., Jacobs, B. P., Costello, A. J. & Cummings, S. R. Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemp. Clin. Trials 38, 190\u2013197 (2014).","journal-title":"Contemp. Clin. Trials"},{"key":"162_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJMra1603773","volume":"376","author":"SR Cummings","year":"2017","unstructured":"Cummings, S. R. & Rowbotham, M. C. Electronic informed consent and inernet based trials. N. Engl. J. Med. 376, 856\u2013857 (2017).","journal-title":"N. Engl. J. Med."},{"key":"162_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/01.md.0000172299.72364.95","volume":"84","author":"BP Jacobs","year":"2005","unstructured":"Jacobs, B. P., Bent, S., Tice, J. A., Blackwell, T. & Cummings, S. R. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine 84, 197\u2013207 (2005).","journal-title":"Medicine"},{"key":"162_CR21","doi-asserted-by":"publisher","unstructured":"Cummings, S. R., Lui, L. Y., Eastell, R. & Allen, I. E. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2019.2779 (2019).","DOI":"10.1001\/jamainternmed.2019.2779"},{"key":"162_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427\u2013442 (1967).","journal-title":"Neurology"},{"key":"162_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1210\/er.2001-3002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney, A. et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev. 23, 517\u2013523 (2002).","journal-title":"Endocr. Rev."},{"key":"162_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJMra1603773","volume":"376","author":"C Grady","year":"2017","unstructured":"Grady, C. et al. Informed consent. N. Engl. J. Med. 376, 856\u2013867 (2017).","journal-title":"N. Engl. J. Med."},{"key":"162_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058603","volume":"8","author":"MC Rowbotham","year":"2013","unstructured":"Rowbotham, M. C., Astin, J., Greene, K. & Cummings, S. R. Interactive informed consent: randomized comparison with paper consents. PLoS ONE 8, e58603 (2013).","journal-title":"PLoS ONE"},{"key":"162_CR26","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"162_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1460458214556373","volume":"22","author":"A Abdolahi","year":"2016","unstructured":"Abdolahi, A. et al. A feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders. Health Inform. J. 22, 304\u2013311 (2016).","journal-title":"Health Inform. J."},{"key":"162_CR28","doi-asserted-by":"publisher","unstructured":"Abdolahi, A., Scoglio, N., Killoran, A., Dorsey, E. R. & Biglan, K. M. Potential reliability and validity of a modified version of the Unified Parkinson\u2019s Disease Rating Scale that could be administered remotely. Parkinsonism Relat. Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.10.008 (2012).","DOI":"10.1016\/j.parkreldis.2012.10.008"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00162-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T21:48:02Z","timestamp":1670017682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00162-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1038\/s41531-021-00162-1","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"3 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Caroline M. Tanner receives grants from the Michael J. Fox Foundation, the Parkinson\u2019s Foundation, the Department of Defense, BioElectron, Roche\/Genentech, Biogen Idec and the National Institutes of Health, compensation for serving on Data Monitoring Committees from Voyager Therapeutics, Intec Pharma and Cadent Therapeutics and personal fees for consulting from Neurocrine Biosciences, Adamas Therapeutics, Grey Matter, Acorda, Acadia, Amneal, Lundbeck and CNS Ratings. Steven R. Cummings Receives consulting and grant support from Amgen and Radius and consulting from UCB Pharma. Michael A. Schwarzschild has within the past three years received funding from the Cure Parkinson\u2019s Trust, CBD Solutions trust, Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF), Prevail Therapeutics, Denali Therapeutics and nQ Medical for serving on their scientific advisory boards; from Eli Lilly and Company for serving on a trial Data Monitoring Committee; from Biotie Therapeutics, Inc.\/Acorda Therapeutics, MJFF, Parkinson\u2019s Foundation and Univ. of California-San Francisco for serving on study steering committees; and from Denali Therapeutics for presenting a seminar. He has within the past three years received research funding from the NIH, Parkinson\u2019s Foundation, U.S. Department of Defense, RJG Foundation, Target ALS Foundation, MJFF and the Farmer Family Foundation. Ethan G. Brown receives research support from the Michael J. Fox Foundation, Biogen Idec, and the Gateway Institute for Brain Science. He receives honorarium from NEJM Knowledge+ for his role as the Neurology Section Editor. He also has received personal fees for consulting from Oscar Insurance Corporation and Rune Labs. E Ray Dorsey has served as a consultant to 23andMe, Abbott, Abbvie, Amwell, Biogen, Clintrex, CuraSen, DeciBio, Denali Therapeutics, GlaxoSmithKline, Grand Rounds, Huntington Study Group, Informa Pharma Consulting, medical-legal services, Mednick Associates, Medopad, Olson Research Group, Origent Data Sciences, Inc., Pear Therapeutics, Prilenia, Roche, Sanofi, Shire, Spark Therapeutics, Sunovion Pharmaceuticals, Voyager Therapeutics, and ZS Consulting. He has received honoraria from the Alzheimer\u2019s Drug Discovery Foundation, American Academy of Neurology, American Neurological Association, California Pacific Medical Center, Excellus BlueCross BlueShield, Food and Drug Administration, MCM Education, Michael J. Fox Foundation, Stanford University, UC Irvine, and University of Michigan. He has received research support from Abbvie, Acadia Pharmaceuticals, AMC Health, BioSensics, Burroughs Wellcome Fund, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health, Nuredis, Inc., Patient-Centered Outcomes Research Institute, Pfizer, PhotoPharmics, Roche, and the Safra Foundation. Dr. Dorsey provides editorial services for Karger Publications has ownership interests in Grand Rounds, an online second opinion service. Alberto J. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant\/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, InTrance, Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Acadia, and Sunovion. Nicholas B. Galifianakis receives grant support from the National Institutes of Health and the Boston Scientific Corporation. Samuel M. Goldman receives grant support from Michael J. Fox Foundation, the Department of Defense, Biogen Idec, the National Institutes of Health, the Agency for Toxic Substances and Disease Registry, the American Academy of Pediatrics, the National Institute of Occupational Safety and Health, the Health Resources and Services Administration, and the Veterans Administration Office of Research and Development. Irene Litvan research is supported by the National Institutes of Health grants: 5P50AG005131-33, 2R01AG038791-06A, U01NS090259, U01NS100610, U01NS80818, R25NS098999, P20GM109025; U19 AG063911-1; Parkinson Study Group, Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, Roche, Abbvie, Biogen, EIP-Pharma and Biohaven Pharmaceuticals. She was member of a Lundbeck Advisory Board and participated in a symposium organized by Sunovion. She receives her salary from the University of California San Diego and as Chief Editor of <i>Frontiers in Neurology<\/i>. Nijee Luthra has no disclosures. Nicholas McFarland has received grant support from the NIH and the Michael J. Fox Foundation, and served as a consultant to AbbVie. He supported by an endowment and University funds. Kyle Mitchell has consulted for Boston Scientific Corporation and Rune Labs, Inc. David Standaert is a member of the faculty of the University of Alabama at Birmingham and is supported by endowment and University funds. Dr. Standaert is an investigator in studies funded by Abbvie, Inc., Avid Radiopharmaceuticals, the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson Research, Alabama Department of Commerce, the Department of Defense, and NIH grants P01NS087997, P50NS108675, R25NS079188, P2CHD086851, P30NS047466, and T32NS095775. He has a clinical practice and is compensated for these activities through the University of Alabama Health Services Foundation. In addition, since January 1, 2019 he has served as a consultant for or received honoraria from Axovant Sciences, Inc., Censa Pharmaceuticals, Abbvie Inc., Grey Matter Technologies, Theravance Inc., the Kennedy Krieger Institute, McGraw Hill Publishers, Sanofi- Aventis, RTI Consultants, Cerevance Inc., Yale University and Michigan State University. Douglas Bauer has no disclosures. Susan L. Greenspan receives research support from Amgen and Radius. James Beck is an employee of the Parkinson\u2019s Foundation. Kenneth W. Lyles: Founder and Equity Owner of Faculty Connections, LLC; Member of the Board of Trustees of the National Osteoporosis Foundations; Inventor or Co-inventor of patents involving the use of zoledronic acid.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}